ArticleDrug delivery and translational research2026
M2 macrophage-derived small extracellular vesicles carrying canagliflozin attenuate experimental asthma.
Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAsthma is a chronic inflammatory disorder characterized by immune dysregulation and structural remodeling of the airways, and current therapies remain insufficient, particularly for patients with refractory asthma. Emerging evidence highlights the importance of immunomodulation and local pulmonary administration in improving therapeutic outcomes. Hence, we developed M2 macrophage-derived small extracellular vesicles (M2-sEVs) carrying canagliflozin (CANA) for asthma.
methodsM2-sEVs were isolated and loaded with CANA via ultrasonication to generate CANA-M2-sEVs. The vesicles were characterized by transmission electron microscopy, dynamic light scattering, zeta potential measurement, and sEV-associated marker analysis. Cellular uptake was evaluated using fluorescence imaging. Therapeutic efficacy was assessed in an ovalbumin (OVA)-induced murine asthma model through histological analysis, cytokine profiling, and gene expression assays. The involvement of the PI3K/AKT signaling pathway was investigated using western blotting and pharmacological modulation.
resultsCANA-M2-sEVs retained vesicular morphology and showed nanoscale size distribution with mildly negative surface charge. CANA-M2-sEVs showed efficient, time-dependent cellular uptake in vitro and exerted therapeutic effects following pulmonary administration in vivo. In vivo, CANA-M2-sEVs significantly alleviated airway inflammation, reduced eosinophilic infiltration, and suppressed Th2-associated cytokine production. Moreover, airway remodeling features, including goblet cell metaplasia and collagen deposition, were markedly attenuated. Mechanistically, CANA-M2-sEVs effectively inhibited PI3K and AKT phosphorylation, while pharmacological activation of this pathway partially reversed their anti-inflammatory effects, supporting the involvement of this pathway.
conclusionThis study suggests that CANA-associated M2-sEVs exert anti-inflammatory and anti-remodeling effects in experimental asthma, partly associated with suppression of PI3K/AKT signaling.
Indexed as
Identifiers
42440252What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.